Justin Stebbing

Dr. Stebbing is a research translational professor at Imperial College, London, Editor of Oncogene and a member of the American Society for Clinical Investigation. He has published over 600 papers and during the Covid-19 pandemic his work starting with artificial intelligence led to an FDA EUA for baricitinib. Dr. Stebbing has combined his medical career with healthcare investing and has worked with Atticus capital, Lansdowne and Vitruvian partners as well as previously chairing the board of BB Healthcare Trust.

Dr. Stebbing originally gained a first-class medical degree from Trinity College Oxford prior to a residency at Johns Hopkins hospital.